Industry
Biotechnology
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 2:35 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 12:37 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 12:19 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 11:07 am
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 8:26 pm
Portfolio Pulse from Benzinga Newsdesk
July 29, 2024 | 11:00 am
Portfolio Pulse from Benzinga Newsdesk
May 21, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 7:00 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 1:36 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 9:36 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.